Chief Business Officer
Camille Landis is the Chief Business Officer of Eidos Therapeutics, bringing extensive experience in biotechnology finance, operations and corporate development. Before joining Eidos, Ms. Landis served as Vice President, Corporate Development at Relypsa. During her tenure, Ms. Landis led strategic planning activities, advised on financing strategy, managed corporate alliances and executed on multiple transactions, including Relypsa’s $1.5B acquisition by Galenica / Vifor Pharma. Prior to Relypsa, Ms. Landis led Corporate Development efforts at Affymax and held multiple roles in finance, business development and commercial operations. Earlier in her career, Ms. Landis served as a life sciences strategy consultant with Frontline Consulting (acquired by Navigant) and as an investment banking analyst with Piper Jaffray’s Healthcare Investment Banking practice helping companies raise capital and advising on mergers and acquisitions.
Ms. Landis holds a M.B.A. from the Haas School of Business, University of California, Berkeley, and a B.A., with honors, in Human Biology from University of St. Thomas, St. Paul, MN.